Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange that on December 16, 2025, Jiangsu Howson Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the Company, and Glenmark Specialty S.A., entered into an exclusive licensing, cooperation and distribution agreement for ametinib. Ametinib is a triple-representative dermal growth factor receptor-tyrosine kinase inhibitor used to treat non-small cell lung cancer. Under the license agreement, the licensor will grant the licensee an exclusive license to develop and commercialize ametinib in the authorized region.

Zhitongcaijing · 2d ago
Hanson Pharmaceuticals announced on the Hong Kong Stock Exchange that on December 16, 2025, Jiangsu Howson Pharmaceutical Group Co., Ltd., a wholly-owned subsidiary of the Company, and Glenmark Specialty S.A., entered into an exclusive licensing, cooperation and distribution agreement for ametinib. Ametinib is a triple-representative dermal growth factor receptor-tyrosine kinase inhibitor used to treat non-small cell lung cancer. Under the license agreement, the licensor will grant the licensee an exclusive license to develop and commercialize ametinib in the authorized region.